| Overall Survival, Progression-free survival, and tumor response benefit supporting initial US food and drug administration approval and indication extension of new cancer drugs … DT Michaeli, T Michaeli Journal of Clinical Oncology 40 (35), 4095-4106, 2022 | 57 | 2022 |
| Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland DT Michaeli, M Mills, P Kanavos Applied health economics and health policy 20 (5), 757-768, 2022 | 31 | 2022 |
| Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention DT Michaeli, JC Michaeli, S Albers, T Boch, T Michaeli American Journal of Cardiovascular Drugs 23 (5), 477-495, 2023 | 25 | 2023 |
| Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA DT Michaeli, M Mills, T Michaeli, A Miracolo, P Kanavos Investigational New Drugs 40, 798–809, 2022 | 24 | 2022 |
| Medical education and mental health during COVID-19: a survey across 9 countries D Michaeli, G Keough, F Perez-Dominguez, F Polanco-Ilabaca, ... International journal of medical education 13, 35-46, 2022 | 24 | 2022 |
| Lifestyle Changes Among Medical Students During COVID-19 Pandemic: A Multicenter Study Across Nine Countries F Perez-Dominguez, F Polanco-Ilabaca, F Pinto-Toledo, D Michaeli, ... Health Education & Behavior 48 (4), 446–454, 2021 | 22 | 2021 |
| FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis T Michaeli, H Jürges, DT Michaeli bmj 381, 2023 | 21 | 2023 |
| Valuation and returns of drug development companies: Lessons for bioentrepreneurs and investors DT Michaeli, HB Yagmur, T Achmadeev, T Michaeli Therapeutic innovation & regulatory science 56 (2), 313-322, 2022 | 18 | 2022 |
| Socio-economic burden of disease: Survivorship costs for bladder cancer JC Michaeli, T Boch, S Albers, T Michaeli, DT Michaeli Journal of Cancer Policy 32, 100326, 2022 | 15 | 2022 |
| Launch sequencing of pharmaceuticals with multiple therapeutic indications: evidence from seven countries M Mills, D Michaeli, A Miracolo, P Kanavos BMC Health Services Research 23 (1), 150, 2023 | 13 | 2023 |
| Value drivers of development stage biopharma companies DT Michaeli, HB Yagmur, T Achmadeev, T Michaeli The European Journal of Health Economics 23, 1287–1296, 2022 | 13 | 2022 |
| Cancer Drug Prices in the United States: Efficacy, Innovation, Clinical Trial Evidence, and Epidemiology DT Michaeli, T Michaeli Value in Health 26 (11), 1590-1600, 2023 | 12 | 2023 |
| Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy DT Michaeli, T Michaeli, S Albers, T Boch, JC Michaeli The European Journal of Health Economics, 1-19, 2023 | 10 | 2023 |
| Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany DT Michaeli, JC Michaeli, T Boch, T Michaeli Cardiovascular drugs and therapy 37 (4), 683-694, 2023 | 9 | 2023 |
| Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa DT Michaeli, S Stoycheva, SM Marcus, W Zhang, JC Michaeli, T Michaeli Clinical Drug Investigation 42 (4), 333-343, 2022 | 8 | 2022 |
| Prostate cancer follow-up costs in Germany from 2000 to 2015 T Michaeli, D Michaeli Journal of Cancer Survivorship 16 (1), 86-94, 2022 | 8 | 2022 |
| Clinical Benefit, Development, Innovativeness, Trials, Epidemiology, and Price for Cancer Drugs and Indications with Multiple Special FDA Designations DT Michaeli, T Michaeli, S Albers, JC Michaeli JNCI: Journal of the National Cancer Institute, 2023 | 7* | 2023 |
| Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy DT Michaeli, JC Michaeli, T Boch, T Michaeli Clinical drug investigation 42 (8), 643-656, 2022 | 7 | 2022 |
| Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition DT Michaeli, T Michaeli Pharmacoeconomics 42 (1), 117-131, 2024 | 6 | 2024 |
| 1696MO Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending DT Michaeli, CT Michaeli Annals of Oncology 34, S927, 2023 | 6 | 2023 |
Julia Caroline MichaeliAsklepios Klinik AltonaVerified email at asklepios.com
